Oncology Institute Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
FY Revenue (est.)
$655.5Mnext fiscal year
FY EPS (est.)
-$0.14next fiscal year
Monitoring Framework
Key Performance Indicators
Consolidated Revenue Quarterly147.4MTarget: 630000000 to 650000000
Adjusted EBITDA Quarterly-2.4MTarget: 0 to 9000000
Capitation Revenue Quarterly26.9M
Specialty Pharmacy Revenue Quarterly87.5MTarget: Continued expansion and attachment rate improvements
Watch Items
- Florida Delegated Lives ExpansionTrigger: Reaching 200,000 Medicare Advantage lives across 25 counties in Florida effective July 1, 2026Action: Monitor onboarding operational costs and progressive margin build-up to ensure regional profitability is sustained.
- Free Cash Flow GenerationTrigger: Full-year 2026 guidance of $5 million to $15 millionAction: Track working capital requirements, capital expenditures on new clinics, and cash collections from capitated contracts.
Research as of 19 Jun 2026